Safinamide (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Safinamide" in Italian language version.

refsWebsite

Global rank Italian rank

4^th place

9^th place

799^th place

22^nd place

2^nd place

7^th place

4web.archive.org

1^st place

1^st place

447^th place

644^th place

2medicines.org.uk

3,823^rd place

low place

68^th place

57^th place

1,712^th place

7,714^th place

low place

low place

low place

low place

1merckgroup.com

low place

low place

1aboutpharma.com

low place

low place

low place

low place

5^th place

26^th place

4,963^rd place

325^th place

aboutpharma.com

Parkinson, Zambon annuncia l’arrivo in Italia di safinamide.

canada.ca

health-products.canada.ca

Health Canada, https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97495 Titolo mancante per url url (aiuto). URL consultato il 21 luglio 2019.

doi.org

dx.doi.org

The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease., vol. 16, 2016, DOI:10.1586/14737175.2016.1150783, PMID 26849427.
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease., vol. 16, 2016, DOI:10.1586/14737175.2016.1150783, PMID 26849427.Perez-Lloret, S; Rascol, O (2016).
Safinamide: From molecular targets to a new anti-Parkinson drug, vol. 67, 2006, DOI:10.1212/wnl.67.7_suppl_2.s18, PMID 17030736.
Clinical pharmacology review of safinamide for the treatment of Parkinson's disease, vol. 5, 2015, DOI:10.2217/nmt.15.46, PMID 26587996.
Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsants, vol. 9, 1999, DOI:10.1016/s0960-894x(99)00415-1, PMID 10498200.
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects, vol. 33, 2012, DOI:10.1002/bdd.1822, PMID 23097240.
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects, vol. 33, 2012, DOI:10.1002/bdd.1822, PMID 23097240.Krösser, Sonja; Marquet, Anne; Gallemann, Dieter; Wolna, Peter; Fauchoux, Nicolas; Hermann, Robert; Johne, Andreas (2012).
Discovery and Development of Safinamide, a New Drug for the Treatment of Parkinson's Disease, vol. 3, 2018, DOI:10.1002/9783527808694.ch14, ISBN 9783527808694.
Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives, vol. 41, 1998, DOI:10.1021/jm970599m, PMID 9484507.
Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis, vol. 51, 2018, DOI:10.1159/000492221, ISSN 1423-0208 (WC · ACNP), PMID 30153669.

endpts.com

(EN) endpts.com, https://endpts.com/after-an-odyssey-of-setbacks-fda-finally-green-lights-newrons-parkinsons-drug-xadago/ Titolo mancante per url url (aiuto). URL consultato il 21 marzo 2017.

europa.eu

ema.europa.eu

Copia archiviata (PDF), su ema.europa.eu. URL consultato il 10 agosto 2022 (archiviato dall'url originale il 17 marzo 2018)."Summary of Product Characteristics for Xadago" Archiviato il 17 marzo 2018 in Internet Archive. (PDF).
Xadago EPAR Public assessment report

fda.gov

accessdata.fda.gov

accessdata.fda.gov, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207145lbl.pdf Titolo mancante per url url (aiuto). URL consultato il 2 aprile 2017.
accessdata.fda.gov, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207145lbl.pdf Titolo mancante per url url (aiuto). URL consultato il 2 aprile 2017."Safinimide label" (PDF).
accessdata.fda.gov, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207145lbl.pdf Titolo mancante per url url (aiuto). URL consultato il 2 aprile 2017."Safinimide label" (PDF).

fda.gov

(EN) fda.gov, https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm547852.htm Titolo mancante per url url (aiuto).

medicines.org.uk

(EN) medicines.org.uk, http://www.medicines.org.uk/emc/medicine/31917 Titolo mancante per url url (aiuto). URL consultato il 2 aprile 2017.
(EN) medicines.org.uk, http://www.medicines.org.uk/emc/medicine/31917 Titolo mancante per url url (aiuto). URL consultato il 2 aprile 2017."Xadago - Summary of Product Characteristics".

merck.de

(DE) http://www.merck.de/de/presse/extNewsDetail.html?newsId=81B6B9E2441C1015C12577D0007DBBCC&newsType=1.

merckgroup.com

Merck Returns Rights for Safinamide to Newron, 21 October 2011.

nih.gov

ncbi.nlm.nih.gov

The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease., vol. 16, 2016, DOI:10.1586/14737175.2016.1150783, PMID 26849427.
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease., vol. 16, 2016, DOI:10.1586/14737175.2016.1150783, PMID 26849427.Perez-Lloret, S; Rascol, O (2016).
Safinamide: From molecular targets to a new anti-Parkinson drug, vol. 67, 2006, DOI:10.1212/wnl.67.7_suppl_2.s18, PMID 17030736.
Clinical pharmacology review of safinamide for the treatment of Parkinson's disease, vol. 5, 2015, DOI:10.2217/nmt.15.46, PMID 26587996.
Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound, vol. 288, 1999, PMID 10027853.
Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsants, vol. 9, 1999, DOI:10.1016/s0960-894x(99)00415-1, PMID 10498200.
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects, vol. 33, 2012, DOI:10.1002/bdd.1822, PMID 23097240.
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects, vol. 33, 2012, DOI:10.1002/bdd.1822, PMID 23097240.Krösser, Sonja; Marquet, Anne; Gallemann, Dieter; Wolna, Peter; Fauchoux, Nicolas; Hermann, Robert; Johne, Andreas (2012).
Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives, vol. 41, 1998, DOI:10.1021/jm970599m, PMID 9484507.
Drug evaluation: Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome, vol. 8, 2007, PMID 17659477.
Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis, vol. 51, 2018, DOI:10.1159/000492221, ISSN 1423-0208 (WC · ACNP), PMID 30153669.

oadoi.org

The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease., vol. 16, 2016, DOI:10.1586/14737175.2016.1150783, PMID 26849427.
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease., vol. 16, 2016, DOI:10.1586/14737175.2016.1150783, PMID 26849427.Perez-Lloret, S; Rascol, O (2016).
Safinamide: From molecular targets to a new anti-Parkinson drug, vol. 67, 2006, DOI:10.1212/wnl.67.7_suppl_2.s18, PMID 17030736.
Clinical pharmacology review of safinamide for the treatment of Parkinson's disease, vol. 5, 2015, DOI:10.2217/nmt.15.46, PMID 26587996.
Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsants, vol. 9, 1999, DOI:10.1016/s0960-894x(99)00415-1, PMID 10498200.
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects, vol. 33, 2012, DOI:10.1002/bdd.1822, PMID 23097240.
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects, vol. 33, 2012, DOI:10.1002/bdd.1822, PMID 23097240.Krösser, Sonja; Marquet, Anne; Gallemann, Dieter; Wolna, Peter; Fauchoux, Nicolas; Hermann, Robert; Johne, Andreas (2012).
Discovery and Development of Safinamide, a New Drug for the Treatment of Parkinson's Disease, vol. 3, 2018, DOI:10.1002/9783527808694.ch14, ISBN 9783527808694.
Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives, vol. 41, 1998, DOI:10.1021/jm970599m, PMID 9484507.
Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis, vol. 51, 2018, DOI:10.1159/000492221, ISSN 1423-0208 (WC · ACNP), PMID 30153669.

pdtrials.org

Study of Safinamide in Early Parkinson's Disease as Add-on to Dopamine Agonist (MOTION)

unibo.it

acnpsearch.unibo.it

Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis, vol. 51, 2018, DOI:10.1159/000492221, ISSN 1423-0208 (WC · ACNP), PMID 30153669.

web.archive.org

Copia archiviata (PDF), su ema.europa.eu. URL consultato il 10 agosto 2022 (archiviato dall'url originale il 17 marzo 2018).
Copia archiviata (PDF), su ema.europa.eu. URL consultato il 10 agosto 2022 (archiviato dall'url originale il 17 marzo 2018)."Summary of Product Characteristics for Xadago" Archiviato il 17 marzo 2018 in Internet Archive. (PDF).
Copia archiviata. URL consultato il 10 agosto 2022 (archiviato dall'url originale il 4 marzo 2016).
Copia archiviata (PDF). URL consultato il 10 agosto 2022 (archiviato dall'url originale il 4 marzo 2016).

worldcat.org

Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis, vol. 51, 2018, DOI:10.1159/000492221, ISSN 1423-0208 (WC · ACNP), PMID 30153669.